Please assess the completion status of the following clinical trial:

Trial Title: Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of any age with diagnosis of:~  * Relapsed/refractory lymphoma (B cell non-Hodgkin) who have lack of objective response to at least two prior chemotherapy regimens~ * Relapsed chronic lymphocytic leukemia with high risk features: lack of objective response or relapse within 6 months following nucleoside-analogue based chemotherapy regimen or patients with 17p deletion CLL who lacked objective response to at least 1 preceding chemotherapy regimen~* Available related HLA haploidentical NK cell donor by at least Class I serologic typing at the A\&B locus (age 12-75 years)~* Karnofsky \> 70% for patients 16 years and older and Lansky play score \> 50 for patients under 16 years of age~* Measurable disease based on modified Response Evaluation Criteria in Solid Tumors (RECIST)~* Have acceptable organ function as defined within 28 days of enrollment:~  * Hematologic: platelets ≥ 80,000 x 10\^9/L; hemoglobin ≥ 9 g/dL, unsupported by transfusions within 7 days; absolute neutrophile count (ANC) ≥ 1000 x 10\^9/L, unsupported by Granulocyte colony-stimulating factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) for 10 days or Neulasta for 21 days - the hematologic requirements are waived for patients with inadequate counts due to known bone marrow involvement by disease who are otherwise eligible~ * Renal: calculated glomerular filtration rate (GFR) \> 50 ml/min~ * Hepatic: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 5 x upper limit of normal and total bilirubin ≤3 mg/dl - hepatic requirements are waived for patients with known disease involvement in the liver if otherwise eligible~ * Pulmonary function: \>40% corrected Carbon Monoxide Diffusing Capacity (DLCO) and Forced expiratory volume in one second (FEV1) (oxygen saturation \[\>92%\] can be used in child where pulmonary function tests (PFT's) cannot be obtained)~ * Cardiac: no symptoms of uncontrolled cardiac disease, left ventricular ejection fraction ≥ 40%~* Able to be off prednisone or other immunosuppressive medications for at least 3 day prior to Day 0 (excluding denileukin diftitox pre-medications)~* Sexually active women of childbearing potential must agree to use adequate contraception (diaphragm, birth control pills, injections, intrauterine device \[IUD\], surgical sterilization, subcutaneous implants, or abstinence, etc.) for the duration of treatment.~* Voluntary written consent~Exclusion Criteria:~* Pregnant or lactating. The agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk. All females of childbearing potential must have a blood test or urine study within 14 days prior to enrollment to rule out pregnancy. Women of childbearing age must use appropriate contraceptive method.~* Active central nervous system (CNS) lymphoma/leukemia - Patients with prior CNS involvement are eligible provided that it has been treated and is in remission.~* Active serious infection (pulmonary infiltrates or lesions are allowed only after the appropriate diagnostic testing is negative for infection or appropriate therapy was initiated for probable infection)~* Pleural effusion large enough to be detectable on chest x-ray (CXR)~* Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology~* Active concurrent malignancy (except skin cancer)~* Epstein-Barr virus (EBV) post-transplant lymphoproliferative disorder~* Positive HBsAg. If HBcAb is positive, Hepatitis B DNA by PCR will be evaluated. Positive anti HBcAb with an undetectable viral load does not exclude the patient.~* Any investigational therapy in the past 30 days~* Patients following allogeneic stem cell transplantation are eligible in the absence of graft versus host disease and are off immunosuppression for at least 30 days~* Known allergy to any of the study agents

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients Receiving NK Cell Infusion (Type: EXPERIMENTAL): Non-Myeloablative Conditioning Using Rituximab, Fludarabine, Cyclophosphamide and Methylprednisolone followed by Interleukin 2-activated Allogeneic Natural Killer Cells infusion for Patients with Refractory NHL and CLL

Based on this trial design, predict the completion outcome and termination type (if applicable).